Luis F. Cisneros-Guzmán
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luis F. Cisneros-Guzmán has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Margarito García Munguía
Universidad Autónoma de Aguascalientes
1 shared publication - Argelia García-Munguía
Tecnológico Nacional de México, Instituto Tecnológico de Pabellón de Arteaga, Carretera a la Estación de Rincón de Romos km 1, Pabellón de Arteaga 20670, Mexico
1 shared publication - Carlos García-Munguía
Univ Guanajuato, Dept Vet & Zootecnia, Carretera Irapuato Silao Km 9, Guanajuato 36500, Mexico
1 shared publication - Carolina Ramírez-López
Centro de Investigación en Biotecnología Aplicada (CIBA), Instituto Politécnico Nacional (IPN), Ex-Hacienda San Juan Molino, Carretera Estatal Tecuexcomac-Tepetitla km 1.5, Tepetitla de Lardizábal 90700, Mexico
1 shared publication - Erik Ocaranza-Sánchez
Centro de Investigación en Biotecnología Aplicada (CIBA), Instituto Politécnico Nacional (IPN), Ex-Hacienda San Juan Molino, Carretera Estatal Tecuexcomac-Tepetitla km 1.5, Tepetitla de Lardizábal 90700, Mexico
1 shared publication - Fabián Correa-Morales
Centro Nacional de Programas Preventivos y Control de Enfermedades, Secretaria de Salud, Ciudad de Mexico, Mexico
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (11) , 1196
Autogenous Vaccines for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Control: Biotechnological Advances and Veterinary Applications
Porcine reproductive and respiratory syndrome virus (PRRSV) remains one of the most economically significant pathogens of global swine production, and its genetic variability limits the field effectiveness of commercially licensed vaccines. Autogenous vaccines prepared from isolates recovered within a defined epidemiological unit are used at scale as a herd-specific alternative. This review distinguishes authorized autogenous products from experimental herd-specific preparations and from precision-vaccinology platforms that are neither authorized nor, given current development timelines, compatible with the autogenous use case. Following a structured search, the primary evidence base for efficacy is synthesized and found to comprise three studies from two research groups, including a single randomized controlled field trial. That evidence supports reductions in viraemia and lung pathology after homologous challenge, but not heterologous protection, and no study reports reproductive outcomes. The regulatory frameworks of the European Union, the United States and Mexico are compared, and are shown to authorize these products without requiring a demonstration of efficacy. Inactivation validation criteria, safety, breeding animals, interference with surveillance, isolate selection, where multiple variants co-circulate, and the absence of published economic evaluation are examined, together with the Latin American context, for which no field experience has been published.
- 5 November 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (11) , 1196
Open AccessAutogenous Vaccines for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Control: Biotechnological Advances and Veterinary Applications
Porcine reproductive and respiratory syndrome virus (PRRSV) remains one of the most economically significant pathogens of global swine production, and its genetic variability limits the field effectiveness of commercially licensed vaccines. Autogenous vaccines prepared from isolates recovered within a defined epidemiological unit are used at scale as a herd-specific alternative. This review distinguishes authorized autogenous products from experimental herd-specific preparations and from precision-vaccinology platforms that are neither authorized nor, given current development timelines, compatible with the autogenous use case. Following a structured search, the primary evidence base for efficacy is synthesized and found to comprise three studies from two research groups, including a single randomized controlled field trial. That evidence supports reductions in viraemia and lung pathology after homologous challenge, but not heterologous protection, and no study reports reproductive outcomes. The regulatory frameworks of the European Union, the United States and Mexico are compared, and are shown to authorize these products without requiring a demonstration of efficacy. Inactivation validation criteria, safety, breeding animals, interference with surveillance, isolate selection, where multiple variants co-circulate, and the absence of published economic evaluation are examined, together with the Latin American context, for which no field experience has been published.